Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

This white paper investigates the research framework to model the expected effects of the decline in health outcomes caused by a decrease in the quantity and quality of pharmaceutical utilization due to the economic effects of a deep and long recession. Four effects caused by a deep recession that will adversely affect the utilization of branded/biologic drugs, which, in turn, will cause a ...

Real world evidence (RWE) has traditionally been leveraged to inform predominantly product development decisions, payer contracts, and health economic and outcome research (HEOR) studies. There is now an increased emphasis on leveraging RWE across a broader range of business functions given the industry shift towards specialty drugs and the treatment of rare diseases. Now with more outcomes-based ...

The movement toward measuring patient outcomes resulting from a specific drug therapy, especially in an environment increasingly focused on specialty medicines, has caused researchers to look at different datasets than previously analyzed. Two patient-based datasets in particular come to mind: 1.) electronic health records (EHR), and 2.) claims data. These two data sources will each be suited to ...

No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service researchers, biopharma industry representatives, and healthcare professionals. However, the “quick and easy fix” option of price controls invariably comes up. While this option is publicly appealing, the question is what (if ...

The pharmacy channel has been an under-studied area by drug companies relative to greater focus on physicians, managed care, hospitals, and patients/consumers. This paper sheds empirical light on the effects of potential pharmacist involvement and motivations in brand-to-generic drug substitutions driven by state pharmacy drug product selection (DPS) laws that have to be later reversed as seen in ...

Improving the quality of care and services to patients and enrollees is one of the key imperatives of the Affordable Care Act (ACA). Several initiatives and measures have been put in place to make this imperative an operational reality across the entire healthcare landscape. For several years, CMS has posted quality ratings of Medicare Advantage plans (STAR Ratings) to help Medicare ...